{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:23:17Z","timestamp":1787674997036,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-026-07477-w","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:08:55Z","timestamp":1787627335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world management of chronic pseudophakic cystoid macular oedema: a descriptive case series of treatment timelines and escalation patterns"],"prefix":"10.1007","author":[{"given":"Amber","family":"Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bence","family":"Tasnadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hassane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohista","family":"Saidkasimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"7477_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2147\/CIA.S111761","volume":"11","author":"A Grzybowski","year":"2016","unstructured":"Grzybowski A et al (2016) Pseudophakic cystoid macular edema: update 2016. Clin Interv Aging 11:1221\u20131229. https:\/\/doi.org\/10.2147\/CIA.S111761","journal-title":"Clin Interv Aging"},{"key":"7477_CR2","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jcrs.2007.05.013","volume":"33","author":"BA Henderson","year":"2007","unstructured":"Henderson BA et al (2007) Clinical pseudophakic cystoid macular edema: risk factors and duration. J Cataract Refract Surg 33:1550\u20131558. https:\/\/doi.org\/10.1016\/j.jcrs.2007.05.013","journal-title":"J Cataract Refract Surg"},{"key":"7477_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41433-020-0908-y","volume":"35","author":"OO Erikitola","year":"2021","unstructured":"Erikitola OO et al (2021) Persistent CME after uncomplicated cataract surgery: Scottish study. Eye (Lond) 35:584\u2013591. https:\/\/doi.org\/10.1038\/s41433-020-0908-y","journal-title":"Eye (Lond)"},{"key":"7477_CR4","first-page":"557","volume":"96","author":"AJ Flach","year":"1998","unstructured":"Flach AJ (1998) Cystoid macular edema after cataract surgery: incidence and treatment. Trans Am Ophthalmol Soc 96:557\u2013634","journal-title":"Trans Am Ophthalmol Soc"},{"key":"7477_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/IIO.0b013e3181c551da","volume":"50","author":"NR Benitah","year":"2010","unstructured":"Benitah NR, Arroyo JG (2010) Pseudophakic cystoid macular edema. Int Ophthalmol Clin 50:139\u2013153","journal-title":"Int Ophthalmol Clin"},{"key":"7477_CR6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00417-018-3954-4","volume":"256","author":"F Schaub","year":"2018","unstructured":"Schaub F et al (2018) Preexisting epiretinal membrane and pseudophakic CME. Graefes Arch Clin Exp Ophthalmol 256:909\u2013917. https:\/\/doi.org\/10.1007\/s00417-018-3954-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7477_CR7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ophtha.2015.10.001","volume":"123","author":"CJ Chu","year":"2016","unstructured":"Chu CJ et al (2016) Risk factors and incidence of macular edema after cataract surgery. Ophthalmology 123:316\u2013323. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.001","journal-title":"Ophthalmology"},{"key":"7477_CR8","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1136\/bjo.2005.073817","volume":"89","author":"S Sivaprasad","year":"2005","unstructured":"Sivaprasad S et al (2005) NSAIDs for CME after cataract surgery: systematic review. Br J Ophthalmol 89:1420\u20131422. https:\/\/doi.org\/10.1136\/bjo.2005.073817","journal-title":"Br J Ophthalmol"},{"key":"7477_CR9","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.ophtha.2014.04.035","volume":"121","author":"L Kessel","year":"2014","unstructured":"Kessel L et al (2014) Prevention of macular edema by steroid and NSAID drops. Ophthalmology 121:1915\u20131924. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.035","journal-title":"Ophthalmology"},{"key":"7477_CR10","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0161-6420(00)00365-1","volume":"107","author":"JS Heier","year":"2000","unstructured":"Heier JS et al (2000) Ketorolac vs prednisolone vs combination therapy for pseudophakic CME. Ophthalmology 107:2034\u20132038","journal-title":"Ophthalmology"},{"key":"7477_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/s0002-9394(14)74268-0","volume":"103","author":"AJ Flach","year":"1987","unstructured":"Flach AJ et al (1987) Ketorolac 0.5% for chronic aphakic and pseudophakic CME. Am J Ophthalmol 103:479\u2013486. https:\/\/doi.org\/10.1016\/s0002-9394(14)74268-0","journal-title":"Am J Ophthalmol"},{"key":"7477_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0002-9394(14)76851-5","volume":"112","author":"AJ Flach","year":"1991","unstructured":"Flach AJ et al (1991) Improvement in visual acuity in chronic pseudophakic CME with ketorolac. Am J Ophthalmol 112:514\u2013519","journal-title":"Am J Ophthalmol"},{"key":"7477_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.survophthal.2014.08.005","volume":"60","author":"S Guo","year":"2015","unstructured":"Guo S et al (2015) Management of pseudophakic CME. Surv Ophthalmol 60:123\u2013137. https:\/\/doi.org\/10.1016\/j.survophthal.2014.08.005","journal-title":"Surv Ophthalmol"},{"key":"7477_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0886-3350(02)01441-4","volume":"29","author":"MD Conway","year":"2003","unstructured":"Conway MD et al (2003) Intravitreal triamcinolone for refractory CME. J Cataract Refract Surg 29:27\u201333. https:\/\/doi.org\/10.1016\/s0886-3350(02)01441-4","journal-title":"J Cataract Refract Surg"},{"key":"7477_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002044","author":"KL Pepple","year":"2018","unstructured":"Pepple KL, Nguyen MH, Pakzad-Vaezi K, Williamson K, Odell N, Lee C, Leveque TK, Van Gelder RN (2018) Response of inflammatory cystoid macular edema to treatment using oral acetazolamide. Retina. https:\/\/doi.org\/10.1097\/IAE.0000000000002044","journal-title":"Retina"},{"key":"7477_CR16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1080\/02713683.2016.1214968","volume":"42","author":"G Mylonas","year":"2017","unstructured":"Mylonas G et al (2017) Dexamethasone implant vs triamcinolone for postoperative CME. Curr Eye Res 42:648\u2013652. https:\/\/doi.org\/10.1080\/02713683.2016.1214968","journal-title":"Curr Eye Res"},{"key":"7477_CR17","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/bjophthalmol-2014-306159","volume":"99","author":"D Bellocq","year":"2015","unstructured":"Bellocq D et al (2015) Dexamethasone implants for post-surgical macular edema: EPISODIC study. Br J Ophthalmol 99:979\u2013983. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-306159","journal-title":"Br J Ophthalmol"},{"key":"7477_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/s0002-9394(02)01938-4","volume":"135","author":"N Benhamou","year":"2003","unstructured":"Benhamou N et al (2003) Intravitreal triamcinolone for refractory pseudophakic CME. Am J Ophthalmol 135:246\u2013249. https:\/\/doi.org\/10.1016\/s0002-9394(02)01938-4","journal-title":"Am J Ophthalmol"},{"key":"7477_CR19","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/112067210701700520","volume":"17","author":"A Konstantopoulos","year":"2007","unstructured":"Konstantopoulos A et al (2007) Intravitreal triamcinolone for refractory CME: review. Eur J Ophthalmol 17:812\u2013821","journal-title":"Eur J Ophthalmol"},{"key":"7477_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3341\/kjo.2006.20.4.205","volume":"20","author":"YJ Choi","year":"2006","unstructured":"Choi YJ et al (2006) Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. Korean J Ophthalmol 20:205\u2013209. https:\/\/doi.org\/10.3341\/kjo.2006.20.4.205","journal-title":"Korean J Ophthalmol"},{"key":"7477_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jcrs.2007.08.021","volume":"34","author":"MS Spitzer","year":"2008","unstructured":"Spitzer MS et al (2008) Bevacizumab for postoperative pseudophakic CME. J Cataract Refract Surg 34:70\u201375. https:\/\/doi.org\/10.1016\/j.jcrs.2007.08.021","journal-title":"J Cataract Refract Surg"},{"key":"7477_CR22","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1089\/tmj.2025.0042","volume":"31","author":"B Tasnadi","year":"2025","unstructured":"Tasnadi B et al (2025) Lessons from a vitreoretinal virtual service in a tertiary center. Telemed J E Health 31:1236\u20131240. https:\/\/doi.org\/10.1089\/tmj.2025.0042","journal-title":"Telemed J E Health"},{"key":"7477_CR23","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.ophtha.2009.04.006","volume":"116","author":"JF Arevalo","year":"2009","unstructured":"Arevalo JF et al (2009) Bevacizumab for refractory pseudophakic CME: PACORES results. Ophthalmology 116:1481\u20131487. https:\/\/doi.org\/10.1016\/j.ophtha.2009.04.006","journal-title":"Ophthalmology"},{"key":"7477_CR24","first-page":"923","volume":"5","author":"T Yilmaz","year":"2011","unstructured":"Yilmaz T et al (2011) Systematic review: bevacizumab for pseudophakic CME. Clin Ophthalmol 5:923\u2013929","journal-title":"Clin Ophthalmol"},{"key":"7477_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/sj.eye.6701895","volume":"20","author":"JP Kersey","year":"2006","unstructured":"Kersey JP, Broadway DC (2006) Corticosteroid-induced glaucoma: review. Eye (Lond) 20:407\u2013416. https:\/\/doi.org\/10.1038\/sj.eye.6701895","journal-title":"Eye (Lond)"},{"key":"7477_CR26","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","volume":"37","author":"A Malcl\u00e8s","year":"2017","unstructured":"Malcl\u00e8s A et al (2017) Safety of intravitreal dexamethasone implant (OZURDEX): SAFODEX study. Retina 37:1352\u20131359. https:\/\/doi.org\/10.1097\/IAE.0000000000001369","journal-title":"Retina"},{"key":"7477_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ophtha.2013.06.033","volume":"121","author":"RN Khurana","year":"2014","unstructured":"Khurana RN et al (2014) Dexamethasone implant migration: risk factors and management. Ophthalmology 121:67\u201371. https:\/\/doi.org\/10.1016\/j.ophtha.2013.06.033","journal-title":"Ophthalmology"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07477-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07477-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07477-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:02:27Z","timestamp":1787673747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07477-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":27,"alternative-id":["7477"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07477-w","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}